HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis.

AbstractBACKGROUND:
Two Leishmania major ribosomal proteins L3 (LmL3) and L5 (LmL5) have been described as protective molecules against cutaneous leishmaniasis due to infection with L. major and Leishmania braziliensis in BALB/c mice when immunized with a Th1 adjuvant (non-methylated CpG-oligodeoxynucleotides; CpG-ODN). In the present study we analyzed the cross-protective efficacy of an LmL3-LmL5-CpG ODN combined vaccine against infection with Leishmania amazonensis and Leishmania chagasi (syn. Leishmania infantum) the etiologic agents of different clinical forms of human leishmaniasis in South America.
METHODS:
The combined vaccine was administered subcutaneously to BALB/c mice. After immunization the cellular and humoral responses elicited were analyzed. Mice were independently challenged with L. amazonensis and L. chagasi. The size of the cutaneous lesions caused by the infection with the first species, the parasite loads and the immune response in both infection models were analyzed nine weeks after challenge.
RESULTS:
Mice vaccinated with the combined vaccine showed a Th1-like response against LmL3 and LmL5. Vaccinated mice were able to delay lesion development due to L. amazonensis infection and to control parasite loads in the site of infection. A reduction of the parasite burden in the lymph nodes draining the site of infection and in the liver and spleen was observed in the vaccinated mice after a subcutaneous infection with L. chagasi. In both models of infection, protection was correlated to parasite antigen-specific production of IFN-γ and down-regulation of parasite-mediated IL-4 and IL-10 responses.
CONCLUSIONS:
The data presented here demonstrate the potential use of L. major L3 and L5 recombinant ribosomal proteins for the development of vaccines against various Leishmania species.
AuthorsLaura Ramirez, Laura Corvo, Mariana C Duarte, Miguel A Chávez-Fumagalli, Diogo G Valadares, Diego M Santos, Camila I de Oliveira, Marta R Escutia, Carlos Alonso, Pedro Bonay, Carlos A P Tavares, Eduardo A F Coelho, Manuel Soto
JournalParasites & vectors (Parasit Vectors) Vol. 7 Pg. 3 (Jan 02 2014) ISSN: 1756-3305 [Electronic] England
PMID24382098 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • CPG-oligonucleotide
  • Cytokines
  • Leishmaniasis Vaccines
  • Oligodeoxyribonucleotides
  • Ribosomal Protein L3
  • Ribosomal Proteins
  • ribosomal protein L5
Topics
  • Animals
  • Cross Reactions (immunology)
  • Cytokines (biosynthesis)
  • Female
  • Immunity, Cellular
  • Immunity, Humoral
  • Leishmania major (immunology)
  • Leishmaniasis Vaccines (immunology)
  • Leishmaniasis, Cutaneous (immunology, prevention & control)
  • Leishmaniasis, Visceral (immunology, prevention & control)
  • Mice
  • Oligodeoxyribonucleotides
  • Ribosomal Protein L3
  • Ribosomal Proteins (immunology)
  • Th1 Cells (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: